ArticleCureus2025
Stereotactic Re-irradiation of Sternal Metastases Using Skin Surface Fiducial Markers and Real-Time Motion Synchronization.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to respiratory motion, treating sternal metastases with stereotactic body radiotherapy (SBRT) is challenging, often requiring large irradiation volumes to account for target movement. To address this, we implemented a straightforward approach by placing skin fiducial markers near the sternal metastasis, enabling real-time motion synchronization with the CyberKnife® System (Accuray Inc., Sunnyvale, CA). Advances in anti-cancer therapies have significantly extended survival in metastatic patients, increasing their likelihood of requiring re-irradiation and experiencing late toxicities. We present the outcomes of two patients, one with metastatic hepatocellular carcinoma (mHCC) and one with metastatic breast cancer (mBC), who underwent two courses of SBRT for sternal metastases using the CyberKnife® and skin fiducial markers for motion management. Both patients tolerated the treatment well, achieving complete pain relief and durable local control. No late toxicity was observed in the mHCC case, while the mBC patient developed significant left anterior descending artery (LAD) stenosis, which may have been linked to cumulative radiation exposure. Given the known risk of cardiac toxicity associated with radiation therapy, these findings underscore the importance of minimizing cardiac dose to reduce long-term toxicity, particularly in re-irradiation cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.